Claim 1: Pharmaceutical composition comprising at least one compound of formula (1) in which the radicals denote: R 1 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, C 6-14 aryl, carboxy or C-thiocarb； in particular hydrogen or C1-3 alkyl； R2 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-14 aryl, carboxy or C-thiocarb； in particular hydrogen or C1-3 alkyl； R3 is hydrogen or C1-8 alkyl, in particular methyl； R4 is OH or O-C1-8 alkyl, in particular OH； R5 is hydrogen or C1-8 alkyl, in particular hydrogen； and / or a pharmaceutically acceptable salt thereof, and / or a stereoisomeric form or a derivative thereof,And at least one cyclopentanediol derivative (c) which can be accepted and selected on the drug, and other components (f): claim 7: any claim that the drug component conforms to 1-6, wherein formula compound (1) has type R, and cyclopentanediol compound (c) from B-hydroxycyclopentadiene Claim 8: any pharmaceutical ingredient referred to in claims 1 to 7,Wherein, the grinding ratio of formula compound (1) and cyclopentanediol compound (c) is between 0.1:1 and 1:20. Requirement 9: a pharmaceutical ingredient according to any one of the requirements from 1 to 8, which is a liquid component of water, accounting for at least 70% by weight, and the concentration of formula compound (1) varies from 1 mg / ml to 50 mg / ml. PharmacyIt is used for the treatment of central nervous system diseases in accordance with any of articles 1 to 10. D. Claim 12: pharmaceutical ingredients in any one of claims 1 to 10for the treatment of an ophthalmic disorder or a disease. Claim 13: Process for the preparation of a pharmaceutical composition comprising the steps of mixing together at least one compound of formula (1) in which the radicals denote: R 1 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, aryl C6-14, carboxy or C-thiocarb； in particular hydrogen or C1-3 alkyl； R2 is hydrogen, C1-8 alkyl, C3-8 cycloalkyl, C6-14 aryl, carboxy or C-thiocarb； in particular hydrogen or C1-3 alkyl； R3 i
